Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | GPX4 | P36969 | 1/20 | 0.34 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cynaropicrin SCHEMBL349976 | 1.00 | MAPT (0.42) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| Cynaropicrin SCHEMBL1711811 | 1.00 | MAPT (0.42) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL10307519 | 0.91 | MAPT (0.43) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| Aguerin B SCHEMBL29352650 | 0.87 | MAPT (0.54) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL10307583 | 0.81 | MAPT (0.35) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL31092250 | 0.81 | MAPT (0.43) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL12516825 | 0.81 | MAPT (0.42) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL31273011 | 0.81 | MAPT (0.42) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| Janerin SCHEMBL30019199 | 0.80 | MAPT (0.51) | MAPTMEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL12459711 | 0.80 | MAPT (0.41) | MAPTMEN1ALDH1A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200055835-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | NEEM BIOTECH LTD (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20200055835-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | NEEM BIOTECH LTD (GB) | 2020-02-20 | — | — | US | disclosed |
| EP-3260449-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | Neem Biotech Ltd. (GB) | 2017-12-27 | — | — | EP | disclosed |
| EP-3260449-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | Neem Biotech Ltd. (GB) | 2017-12-27 | — | — | EP | disclosed |
| EP-2523946-B1 | Tricyclic sesquiterpene lactones for used in the treatment of obesity and related diseases and non-therapeutic treatable conditions | NEEM BIOTECH LTD (GB) | 2017-09-20 | — | — | EP | disclosed |
| US-20130023586-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | INTERMED DISCOVERY GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023586-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | INTERMED DISCOVERY GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023586-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | INTERMED DISCOVERY GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| EP-2523946-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | InterMed Discovery GmbH (DE) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011085979-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | INTERMED DISCOVERY GMBH (DE) | 2011-07-21 | — | — | WO | disclosed |
| EP-2345646-A1 | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions | InterMed Discovery GmbH (DE) | 2011-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055835-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | CETP, LIPC, FABP4 | MAPT 134/4885MEN1 3533/4885ALDH1A1 1841/4885 |
| US-20130023586-A1 | USE OF TRICYCLIC SESQUITERPENE LACTONES IN THE TREATMENT OF OBESITY AND RELATED DISEASES AND NON-THERAPEUTIC TREATABLE CONDITIONS | CETP, LIPC, FABP4 | MAPT 134/4885MEN1 3533/4885ALDH1A1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.